AN OPEN-LABEL MULTICENTER PHASE l/1B TRIAL EVALUATING THE SAFETY ANDPHARMACOKINETICS OF ESCALATING DOSES OF BTCT4465A AS A SINGLE AGENT ANDCOMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORYB-CELL NON-HODGKIN S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Relapsed Or Refractory B-cell Non-hodgkin’s Lymphoma And Chronic Lymphocytic Leukemia
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1 . History of one of the following histologically-documented hematologic malignancies: Follicular Lymphoma; Marginal Zone Lymphoma (MZL), transformed Follicular Lymphoma, Richter s transformation, Diffuse large B-cell lymphoma (DLBCL), Primary mediastinal B-ceil lymphoma (PMBCL), Small lymphocytic lymphoma (SLL), or Mantle cell lymphoma (MCL) Patients with Richter's transformation 2. Patient has relapsed after or failed to respond to at least one prior treatment regimen

You may not be eligible for this study if the following are true:

  • 1. Prior use of any monoclonal antibody, radioimmunoconjugate or antibody-drug conjugate within 4 weeks before first BTCT4465A infusion 2. Prior treatment with systemic immunotherapeutic agents, including but not limited to cytokine therapy and anti-CTi_A4, antiED-1 and antiPD-L1 therapeutic antibodies, within 12 weeks of first BTCT4465A infusion 3. Treatment with any chemotherapeutic agent, or treatment with any other anti-cancer agent (investigational or otherwise) within 4 weeks of first BTCT4465A infusion


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.